Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T22:26:27.010Z.
Consensus retrieved: 2026-10-06T10:36:58.645Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T22:26:27.010Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1719e487edf1987d8b1f0a43ac2cfa0d2aa61af237e007c9f807b404ec58ada8
Forward PE Ratio (N/A) = Dated Quote Price ($0.48) / Consensus Forward EPS ($-1.44)
FORWARD PE RATIO
N/A
Citius Pharmaceuticals, Inc.
Market Cap
$13.20M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | $13.20M | N/A |
| Passage Bio, Inc. (PASG)vs › | $13.11M | N/A |
| Optimi Health Corp. (OPTH)vs › | $13.30M | N/A |
| IN8bio, Inc. (INAB)vs › | $13.33M | N/A |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $12.78M | N/A |
| Obsidian Therapeutics Inc. (OBX)vs › | $13.75M | N/A |
| Tempest Therapeutics, Inc. (TPST)vs › | $12.58M | N/A |
| Sintx Technologies, Inc. (SINT)vs › | $13.86M | N/A |
| Dare Bioscience, Inc. (DARE)vs › | $12.48M | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.44M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2027-09-30
At the dated quote price of $0.48, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-09-30 | $-1.44 | $-1.44 – $-1.44 | 1 | n/m |
| 2028-09-30 | $-0.67 | $-0.67 – $-0.67 | 1 | n/m |
| 2029-09-30 | $-0.10 | $-0.10 – $-0.10 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
